Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-κB and Akt signaling pathways in renal cancer cells

Journal of Cellular Biochemistry

Volumn 109, Issue 5, 2010, Pages 885-895

  Lee, Tae Jin ^a,b   Jang, Ji Hoon ^a   Noh, Hyo Jeong ^b   Park, Eun Jung ^a   Choi, Kyeong Sook ^c   Kwon, Taeg Kyu ^a  

^a Keimyung University   (South Korea)

^b Yeungnam University College of Medicine   (South Korea)

^c Ajou University School of Medicine   (South Korea)

Author keywords

Akt; Apoptosis; DR5; NF KB; Par 4; TRAIL

Indexed keywords

CASPASE 3; CASPASE 8; EFFECTOR CASPASE; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATOR CASPASE; LEUCINE; LEUCINE ZIPPER PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL SURFACE; GEL MOBILITY SHIFT ASSAY; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SENSITIZATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, CD95; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL LINE, TUMOR; CYCLOHEXIMIDE; ENZYME ACTIVATION; HUMANS; KIDNEY NEOPLASMS; LEUCINE ZIPPERS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DEATH DOMAIN; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77950415105     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22504     Document Type: Article

References (38)

1. Almasan A, Ashkenazi A. 2003. Apo2L/TRAIL: Apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14:337-348.
2. Baek WK, Park JW, Lim JH, Suh SI, Suh MH, Gabrielson E, Kwon TK. 2002. Molecular cloning and characterization of the human budding uninhibited by benomyl (BUB3) promoter. Gene 295:117-123.
3. BergmannM, Kukoc-Zivojnov N, Chow KU, Trepohl B, Hoelzer D, Weidmann E, Mitrou PS, Boehrer S. 2004. Prostate apoptosis response gene-4 sensitizes neoplastic lymphocytes to CD95-induced apoptosis. Ann Hematol 83:646-653.
4. Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, Trepohl B, Schneider B, Hoelzer D, Mitrou PS, Chow KU. 2006. Prostate-apoptosis-response- gene-4 increases sensitivity to TRAIL-induced apoptosis. Leuk Res 30:597-605.
5. Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM. 2009. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138:377-388.
6. Camandola S, Mattson MP. 2000. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression. J Neurosci Res 61:134-139.
7. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. 2001. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61:7255-7263.
8. Chendil D, Das A, Dey S, Mohiuddin M, Ahmed MM. 2002. Par-4, a proapoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther 1:152-160.
9. Chu L, Gu J, He Z, Xiao T, Liu X. 2006. Adenoviral vector expressing CYLD augments antitumor activity of TRAIL by suppression of NF-kappaB survival signaling in hepatocellular carcinoma. Cancer Biol Ther 5:615-622.
10. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM. 1999. Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205-1208.
11. de Thonel A, Bettaïeb A, Jean C, Laurent G, Quillet-Mary A. 2001. Role of protein kinase C zeta isoform in Fas resistance of immature myeloid KG1a leukemic cells. Blood 98:3770-3777.
12. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. 1997. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 388:300-304.
13. Diaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L, Moscat J. 1996. The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86:777-786.
14. Diaz-Meco MT, Lallena MJ, Monjas A, Frutos S, Moscat J. 1999. Inactivation of the inhibitory kappaB protein kinase/nuclear factor kappaB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J Biol Chem 274:19606-19612.
15. El-Guendy N, Rangnekar VM. 2003. Apoptosis by Par-4 in cancer and neurodegenerative diseases. Exp Cell Res 283:51-66.
16. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R, Rangnekar VM. 2003. Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23:5516-5525.
17. Fraizer G, Leahy R, Priyadarshini S, Graham K, Delacerda J, Diaz M. 2004. Suppression of prostate tumor cell growth in vivo by WT1, the Wilms' tumor suppressor gene. Int J Oncol 24:461-471.
18. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM. 2005. Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 20:33-44.
19. Goswami A, Ranganathan P, Rangnekar VM. 2006. The phosphoinositide 3-kinase/Akt1/Par-4 axis: A cancer-selective therapeutic target. Cancer Res 66:2889-2892.
20. Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C, Bousquet C. 2003. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA 100:155-160.
21. Gurumurthy S, Vasudevan KM, Rangnekar VM. 2001. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev 20:225-243.
22. Gurumurthy S, Goswami A, Vasudevan KM, Rangnekar VM. 2005. Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25:1146-1161.
23. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi Y. 1996. A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16:6945-6956.
24. Joshi J, Fernandez-Marcos PJ, Galvez A, Amanchy R, Linares JF, Duran A, Pathrose P, Leitges M, Cañamero M, Collado M, Salas C, Serrano M, Moscat J, Diaz-Meco MT. 2008. Par-4 inhibits Akt and suppresses Ras-induced lung tumorigenesis. EMBO J 27:2181-2193.
25. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A. 2005. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 280:2205-2212.
26. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, Logsdon CD, Abbruzzese JL, McConkey DJ. 2006. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 5:2251-2260.
27. Lee TJ, Lee JT, Kim SH, Choi YH, Song KS, Park JW, Kwon TK. 2008. Overexpression of Par-4 enhances thapsigargin-induced apoptosis via downregulation of XIAP and inactivation of Akt in human renal cancer cells. J Cell Biochem 103:358-368.
28. Lee JT, Lee TJ, Kim CH, Kim NS, Kwon TK. 2009. Over-expression of reticulon 3 (RTN3) enhances TRAIL-mediated apoptosis via up-regulation of death receptor 5 (DR5) and down-regulation of c-FLIP. Cancer Lett 279:185-192.
29. Moscat J, Diaz-Meco MT. 2003. Par-4 keeps the atypical PKCs at bay. Cell Cycle 2:71-72.
30. Page G, Kögel D, Rangnekar V, Scheidtmann KH. 1999. Interaction partners of Dlk/ZIP kinase: Co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 18:7265-7273.
31. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. 1996. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271:12687-12690.
32. Sells SF, Wood DP, Jr., Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S, Rangnekar VM. 1994. Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5:457-466.
33. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, Gillis D, Liu G, Nair P, Monnig S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DP, Jr., McRoberts JW, Shi Y, Rangnekar VM. 1997. Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17:3823-3832.
34. Smith MR, Jin F, Joshi I. 2007. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 13:5528s-5534s.
35. Song G, Ouyang G, Bao S. 2005. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9:59-71.
36. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML. 2000. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 275:23319-23325.
37. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. 2007. TRAIL therapy in non-small cell lung cancer cells: Sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 6: 2103-2112.
38. Wu YY, Chang YC, Hsu TL, Hsieh SL, Lai MZ. 2004. Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3. J Biol Chem 279:44211-44218.